LeMaitre Vascular (LMAT) Competitors

Glaukos (NYSE:GKOS) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Does the media prefer GKOS or LMAT?

In the previous week, Glaukos had 17 more articles in the media than LeMaitre Vascular. MarketBeat recorded 21 mentions for Glaukos and 4 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.70 beat Glaukos' score of 0.56 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer GKOS or LMAT?

LeMaitre Vascular received 66 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 70.60% of users gave LeMaitre Vascular an outperform vote while only 64.93% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Glaukos	Outperform Votes 448 64.93%	Underperform Votes 242 35.07%
LeMaitre Vascular	Outperform Votes 514 70.60%	Underperform Votes 214 29.40%

Is GKOS or LMAT more profitable?

LeMaitre Vascular has a net margin of 19.40% compared to Glaukos' net margin of -42.43%. LeMaitre Vascular's return on equity of 13.15% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-42.43%	-18.99%	-11.47%
LeMaitre Vascular	19.40%	13.15%	11.47%

Do analysts rate GKOS or LMAT?

Glaukos currently has a consensus target price of $159.42, suggesting a potential upside of 0.92%. LeMaitre Vascular has a consensus target price of $94.63, suggesting a potential downside of 6.24%. Given Glaukos' stronger consensus rating and higher possible upside, equities analysts clearly believe Glaukos is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
LeMaitre Vascular	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89

Do insiders and institutionals hold more shares of GKOS or LMAT?

99.0% of Glaukos shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 6.4% of Glaukos shares are held by insiders. Comparatively, 10.8% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable valuation & earnings, GKOS or LMAT?

LeMaitre Vascular has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$314.71M	27.68	-$134.66M	-$3.02	-52.31
LeMaitre Vascular	$193.48M	11.73	$30.10M	$1.83	55.15

Which has more risk and volatility, GKOS or LMAT?

Glaukos has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Summary

LeMaitre Vascular beats Glaukos on 10 of the 18 factors compared between the two stocks.